Details

Autor(en) / Beteiligte

• Collinge, John, MD
• Gorham, Michele, RN
• Hudson, Fleur, BA
• Kennedy, Angus, MD
• Keogh, Geraldine
• Pal, Suvankar, MRCP
• Rossor, Martin, MD
• Rudge, Peter, FRCP
• Siddique, Durre, PhD
• Spyer, Moira, PhD
• Thomas, Dafydd, MD
• Walker, Sarah, PhD
• Webb, Tom, BSc
• Wroe, Steve, MD
• Darbyshire, Janet, FRCP

Titel

Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial

Ist Teil von

• Lancet neurology, 2009-04, Vol.8 (4), p.334-344

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2009

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• Summary Background The propagation of prions, the causative agents of Creutzfeldt-Jakob disease and other human prion diseases, requires post-translational conversion of normal cellular prion protein to disease-associated forms. The antimalarial drug quinacrine (mepacrine) prevents this conversion in vitro, and was given to patients with various prion diseases to assess its safety and efficacy in changing the course of these invariably fatal and untreatable diseases. Methods Patients with prion disease were recruited via the UK national referral system and were offered a choice between quinacrine (300 mg daily), no quinacrine, or randomisation to immediate quinacrine or deferred quinacrine in an open-label, patient-preference trial. The primary endpoints were death and serious adverse events possibly or probably related to the study drug. This study is registered, ISRCTN 06722585. Findings 107 patients with prion disease (45 sporadic, two iatrogenic, 18 variant, and 42 inherited) were enrolled, 23 in a pilot study and 84 in the main study. Only two patients chose randomisation; 40 took quinacrine during follow-up (37 who chose it at enrolment). Choice of treatment was associated with disease severity, with those least and most severely affected more likely to choose not to receive quinacrine. 78 (73%) patients died: one randomly assigned to deferred treatment, 26 of 38 who chose immediate quinacrine, and 51 of 68 who chose no quinacrine. Although adjusted mortality was lower in those who chose to take quinacrine than in those who did not, this was due to confounding with disease severity, and there was no difference in mortality between groups after adjustment. Four of 40 patients who took quinacrine had a transient response on neurological rating scales. Only two of 14 reported serious adverse events were judged quinacrine-related. Interpretation Quinacrine at a dose of 300 mg per day was reasonably tolerated but did not significantly affect the clinical course of prion diseases in this observational study. Funding Department of Health (England); UK Medical Research Council.